Sunny Pharmtech

Sunny Pharmtech Interest Coverage

The Interest Coverage Ratio of Sunny Pharmtech (6676.TWO) as of Nov 22, 2026 is -26.25. In the previous year, Interest Coverage Ratio was -10.73 — a change of 144.64% (lower).

Interest Coverage

-26.25

YoY

144.64%

Last updated:

Interest Coverage Ratio of Sunny Pharmtech is 2024 -26.25 . Interest Coverage Ratio of Sunny Pharmtech was 2023 -10.73 . It decreases by 144.64% lower compared to the previous year.

The Sunny Pharmtech Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
-269.12 TWD
Jan 1, 2019
-14.35 TWD
Jan 1, 2020
-2.32 TWD
Jan 1, 2021
-20.84 TWD
Jan 1, 2022
-14.49 TWD
Jan 1, 2023
-10.73 TWD
Jan 1, 2024
-26.25 TWD
The Sunny Pharmtech Interest Coverage history
YEARInterest CoverageYoY
-26.25+144.64%
-10.73-25.96%
-14.49-30.45%
-20.84+797.07%
-2.32-83.81%
-14.35-94.67%
-269.12—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sunny Pharmtech Stock analysis

What does Sunny Pharmtech do? Sunny Pharmtech Inc develops, manufactures, and markets generic and 505(b)2 drug products, primarily targeting the United States market. The company's main products include lectin drug complex (LDC) anesthesia analgesic ointment, neurofibrillary tangle (NFT) anti-urinary tract infection capsules, anti-mitochondrial antibody (AMA) hemostatic lozenges, cyclosporine A (CYA) injections for anemia, and campto (CPT) gynecological injections. These products are sold directly to customers in the United States, generating revenue through pharmaceutical sales. The company focuses on developing and commercializing specialized drug formulations, with its product portfolio centered on LDC, NFT, AMA, CYA, and CPT branded medications. Sales are concentrated in the United States, where the firm's generic and 505(b)2 drug products are marketed to healthcare providers and pharmacies. Revenue is derived from the direct sale of these pharmaceutical products to U.S. customers. Sunny Pharmtech Inc's business model relies on the development and marketing of its proprietary drug formulations, including LDC, NFT, AMA, CYA, and CPT products, which are sold to the United States market. The company's revenue stream is generated through the sale of these branded pharmaceutical products to U.S. healthcare institutions and retail pharmacies. Sunny Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sunny Pharmtech stock

Interest Coverage Ratio of Sunny Pharmtech is -26.25 in 2024.

Interest Coverage Ratio of Sunny Pharmtech changed from -10.73 to -26.25, representing a 144.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Sunny Pharmtech since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Sunny Pharmtech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Sunny Pharmtech

All Key Metrics — Sunny Pharmtech